Select Publications
Journal articles
2017, 'P10 Injecting risk behaviours among people who inject drugs in an Australian prison setting, 2005–2014: the HITS-p study', Journal of Virus Eradication, 3, pp. 15 - 16, http://dx.doi.org/10.1016/s2055-6640(20)30751-2
,2016, 'Hospitalization for anxiety and mood disorders in HIV-infected and -uninfected gay and bisexual men', Journal of Acquired Immune Deficiency Syndromes, 73, pp. 589 - 597, http://dx.doi.org/10.1097/QAI.0000000000001147
,2016, 'Hospitalization for Anxiety and Mood Disorders in HIV-Infected and -Uninfected Gay and Bisexual Men.', J Acquir Immune Defic Syndr, 73, pp. 589 - 597, http://dx.doi.org/10.1097/QAI.0000000000001147
,2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)', Journal of Hepatology, 65, pp. 1086 - 1093, http://dx.doi.org/10.1016/j.jhep.2016.08.010
,2016, 'Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study', Journal of Hepatology, 65, pp. 879 - 887, http://dx.doi.org/10.1016/j.jhep.2016.06.025
,2016, 'Patterns of Drug Use and Drug-related Hospital Admissions in HIV-Positive and -Negative Gay and Bisexual Men', AIDS and Behavior, 20, pp. 2372 - 2386, http://dx.doi.org/10.1007/s10461-016-1303-3
,2016, 'Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis', The Lancet HIV, 3, pp. e351 - e360, http://dx.doi.org/10.1016/S2352-3018(16)30015-7
,2016, 'Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study', Clinical Pharmacokinetics, 55, pp. 861 - 873, http://dx.doi.org/10.1007/s40262-015-0360-5
,2016, 'Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: Week 48 Results of the randomized, multicenter March study', Clinical Infectious Diseases, 63, pp. 122 - 132, http://dx.doi.org/10.1093/cid/ciw207
,2016, 'Poor record linkage sensitivity biased outcomes in a linked cohort analysis', Journal of Clinical Epidemiology, 75, pp. 70 - 77, http://dx.doi.org/10.1016/j.jclinepi.2016.01.023
,2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, 16, pp. 241, http://dx.doi.org/10.1186/s12879-016-1567-2
,2016, 'Hospitalisation rates and associated factors in community-based cohorts of HIV-infected and -uninfected gay and bisexual men', HIV Medicine, 17, pp. 327 - 339, http://dx.doi.org/10.1111/hiv.12312
,2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, 13, pp. 32, http://dx.doi.org/10.1186/s12985-016-0482-x
,2016, 'Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia pacific region: A systematic review and meta-analysis', AIDS Reviews, 18, pp. 69 - 80
,2015, 'Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS ONE (2015)10:2 (e0118228) Doi: 10.1371/journal.pone.0118228 ))', PLoS ONE, 10, pp. e0140623, http://dx.doi.org/10.1371/journal.pone.0140623
,2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, 26, pp. 976 - 983, http://dx.doi.org/10.1016/j.drugpo.2015.05.003
,2015, 'Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study', Clinical Pharmacology and Therapeutics, 98, pp. 406 - 416, http://dx.doi.org/10.1002/cpt.156
,2015, 'Corrigendum to "The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort study" [Drug Alcohol Depend. 152C (2015) 264-271] DOI: 10.1016/j.drugalcdep.2015.03.026', Drug and Alcohol Dependence, 154, pp. 304, http://dx.doi.org/10.1016/j.drugalcdep.2015.06.024
,2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study', Journal of Viral Hepatitis, 22, pp. 708 - 717, http://dx.doi.org/10.1111/jvh.12384
,2015, 'The influence of hepatitis C virus genetic region on phylogenetic clustering analysis', PLoS ONE, 10, pp. e0131437, http://dx.doi.org/10.1371/journal.pone.0131437
,2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5
,2015, 'The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort study', Drug and Alcohol Dependence, 152, pp. 264 - 271, http://dx.doi.org/10.1016/j.drugalcdep.2015.03.026
,2015, 'Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.', AIDS, 29, pp. 911 - 919, http://dx.doi.org/10.1097/QAD.0000000000000625
,2015, 'Patterns of hepatitis C Virus RNA levels during acute infection: The InC3 study', PLoS ONE, 10, pp. e0122232, http://dx.doi.org/10.1371/journal.pone.0122232
,2015, 'Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: A randomized controlled trial', Clinical Infectious Diseases, 60, pp. 1026 - 1032, http://dx.doi.org/10.1093/cid/ciu976
,2015, 'Examining the quality of name code record linkage: What is the impact on death and cancer risk estimates? A validation study', Australian and New Zealand Journal of Public Health, 39, pp. 141 - 147, http://dx.doi.org/10.1111/1753-6405.12287
,2015, 'Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: A 15-year observational cohort study', Drug and Alcohol Dependence, 148, pp. 213 - 216, http://dx.doi.org/10.1016/j.drugalcdep.2014.12.027
,2015, 'Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection', PLoS ONE, 10, pp. e0118228, http://dx.doi.org/10.1371/journal.pone.0118228
,2015, 'Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis', The Lancet HIV, 2, pp. e42 - e51, http://dx.doi.org/10.1016/S2352-3018(14)00061-7
,2015, 'Limited reporting of major harms in studies of initial combination antiretroviral therapy: A systematic review', AIDS, 29, pp. 921 - 929, http://dx.doi.org/10.1097/QAD.0000000000000633
,2015, 'Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment', Journal of Hepatology, 62, pp. 269 - 277, http://dx.doi.org/10.1016/j.jhep.2014.09.001
,2015, 'Diagnosis of hepatitis c virus infection after entry to opioid substitution therapy', Drug and Alcohol Dependence, 156, pp. e122 - e122, http://dx.doi.org/10.1016/j.drugalcdep.2015.07.337
,2015, 'P16.18 Influence of baseline characteristics on the increase cd4 >350 cells/mm3 among HIV/AIDS patients receiving antiretroviral therapy in indonesia', Sexually Transmitted Infections, 91, pp. A218.1 - A218, http://dx.doi.org/10.1136/sextrans-2015-052270.565
,2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study', Journal of Clinical Virology, 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027
,2014, 'A prospective study of hepatitis C incidence in Australian prisoners', Addiction (Abingdon, England), 109, pp. 1695 - 1706, http://dx.doi.org/10.1111/add.12643
,2014, 'A prospective study of hepatitis C incidence in Australian prisoners', Addiction (Abingdon, England), 109, pp. 1695 - 1706, http://dx.doi.org/10.1111/add.12643
,2014, 'Dynamics of HCV RNA Levels During Acute Hepatitis C Virus Infection', Journal of Medical Virology, 86, pp. 1722 - 1729, http://dx.doi.org/10.1002/jmv.24010
,2014, 'A new method for assessing how sensitivity and specificity of linkage studies affects estimation', PLoS ONE, 9, pp. e103690, http://dx.doi.org/10.1371/journal.pone.0103690
,2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, http://dx.doi.org/10.1097/QAI.0000000000000288
,2014, 'Inaccurate ascertainment of morbidity and mortality due to influenza in administrative databases: A population-based record linkage study', PLoS ONE, 9, pp. e98446, http://dx.doi.org/10.1371/journal.pone.0098446
,2014, 'Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: A systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up', PLoS ONE, 9, http://dx.doi.org/10.1371/journal.pone.0097482
,2014, 'Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, 9, pp. e94858, http://dx.doi.org/10.1371/journal.pone.0094858
,2014, 'HLA Alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, 9, pp. e93333, http://dx.doi.org/10.1371/journal.pone.0093333
,2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ ritonavir compared with standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, 67, pp. 161 - 168, http://dx.doi.org/10.1097/QAI.0000000000000288
,2014, 'Comparison of central and local HIV-1 RNA quantification from two international clinical trials', AIDS, 28, pp. 2480 - 2483, http://dx.doi.org/10.1097/QAD.0000000000000461
,2014, 'Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial', The Lancet, 383, pp. 1474 - 1482, http://dx.doi.org/10.1016/S0140-6736(13)62187-X
,2014, 'Lower life expectancy among people with an HCV notification: A population-based linkage study', Journal of Viral Hepatitis, 21, pp. e10 - e18, http://dx.doi.org/10.1111/jvh.12245
,2014, 'The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection', Hepatology, 59, pp. 109 - 120, http://dx.doi.org/10.1002/hep.26639
,2013, 'Characterization of Transcription Factor Phenotypes within Antigen-Specific CD4+ T Cells Using Qualitative Multiplex Single-Cell RT-PCR', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0074946
,2013, 'Dental foundation year 2 training in oral and maxillofacial surgery units - the trainees' perspective', BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 51, pp. E155 - E164, http://dx.doi.org/10.1016/j.bjoms.2012.06.001
,